Carcinogenesis, Teratogenesis & Mutagenesis ›› 2006, Vol. 18 ›› Issue (6): 485-487.doi: 10.3969/j.issn.1004-616x.2006.06.020

Previous Articles     Next Articles

Multidisciplinary Therapy to Clinical Stage IB-IIB Cervical Cancer

ZHOU Li, LI Yan, ZHU An-na, XU Man-man   

  1. (Department of Gynecologic Surgery, Affiliated Tumor Hospital, Shantou University Medical College, Shantou 515031, China)
  • Received:2006-03-14 Revised:2006-06-20 Online:2006-11-30 Published:2006-11-30
  • Contact: ZHOU Li

Abstract: 【ABSTRACT】BACKGROUND & AIM: To investigate the efficacy of individualized multidisciplinary therapy in patients with clinical stage IB-IIB cervical carcinoma. MATERIALS AND METHODS: From Jan 1996 to Dec 2003, 204 patients with clinical stage IB-IIB cervical cancer who were treated with radical hysterectomy and pelvic lymphadenectomy were reviewed retrospectively. RESULTS: The overall 5-year survival rate was(88.04±2.73)%, the median survival time was 37.91 months. The mortality of patients with the poor prognostic factor was not significantly different from that with the low‐risk prognostic factor after multidisciplinary therapy(χ2=3.446,P=0.063). CONCLUSION: A significant benefit of individualized multidisciplinary therapy was proven in cervical carcinoma patients presented in clinical stage IB-IIB. The postoperative radiotherapy or chemotherapy can be used in patients with single poor prognostic factor. However active concurrent radiotherapy and chemotherapy should be delivered to the patients with two or more poor prognostic factors in order to decrease the pelvic recurrence and distant metastasis.

Key words: cervical carcinoma, prognostic factor, multidisciplinary therapy, prognostic

CLC Number: